Mylan NV (NASDAQ: MYL) was founded in 1961, is a company registered in the Netherlands, formerly known as New Moon BV Mylan NV, headquartered in Portersbar, Hertfordshire, UK, with 35,000 full-time employees, together with its affiliates The company develops, licenses, manufactures, markets and distributes generic (i.e. generic drugs), brand generic (generic drugs) and specialty drugs worldwide.
Mylan was founded in 1961 and was listed on the OTC exchange in 1973 under the code MYLN. It was later transferred to Nasdaq in 1976. After 10 years, it was transferred to the New York Stock Exchange in 1986 and the code was changed to MYL. Here, I switched back to Nasdaq, but the code has not changed. A company that knows how to operate capital.
Mylan mainly develops, licenses, manufactures, sells, and distributes branded generic drugs and specialty drugs globally through its subsidiaries. The generic or brand-name generic drug products provided by the company include various tablets, capsules, injections, skin patches, etc. In addition, Mylan also cooperates with other pharmaceutical manufacturers to develop and manufacture drugs, such as: anti-tumor injections, anti-infectives, anesthetics, analgesics, and drugs needed for cardiovascular treatment.
In addition, the company also develops and produces antiretroviral (ARV) finished dosage form (FDF) products and non-ARV FDF products for sale to third parties. The main sales targets are: generic drug wholesalers and distributors of proprietary drugs, group purchasing agencies, chain pharmacies, independent pharmacies, drug manufacturers, institutions, and public and government agencies.
In addition to generic drugs, the company has also developed and produced a batch of proprietary drug products, such as:
- EpiPen-auto-injectable medicine for severe allergic reactions
- Perforomist inhalation solution-treatment of bronchial chronic obstructive pulmonary disease
- ULTIVA-an analgesic used in outpatient surgery, an anesthetic to maintain general anesthesia
Mylan (MYL) acquisition history:
- In 1961, Milan Pharmaceuticals, the predecessor of Mylan, was founded;
- In 1993, Milan Pharmaceuticals acquired Bertek Inc.;
- In 1996, Milan Pharmaceuticals acquired UDL Laboratories;
- In 1999, Milan Pharmaceuticals changed its name to Mylan Technologies Inc.;
- In 2007, it acquired the Generics division of Merck KGaA and renamed it Mylan Laboratories Inc;
- In 2014, the Generics division of Abbott Laboratories was acquired;
- In 2014, acquired Famy Care;
- April 22, 2015, Teva Pharmaceuticals (Teva Pharma) of $ 82 per share in cash and stock for about $ 40.1 billion acquisition of US rival Mylan company (Mylan);
- On May 30, 2015, Mylan Company Mylan rejected the acquisition offer of Teva Pharmaceuticals . Teva increased its stake in MYL to 4.6% and did not give up its attempt to annex.
- On July 26, 2019, Pfizer Pharmaceuticals is planning to merge non-patent assets with Mylan.
Mylan (MYL) investment reference:
It is recommended to also pay attention to another generic drug company: Acron Pharmaceuticals